Baird Financial Group
SRPT icon

Baird Financial Group’s Sarepta Therapeutics SRPT Stock Holding History

Baird Financial Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$230K Buy
12,805
+901
+8% +$17K ﹤0.01% 1827
2026
Q1 		$259K Buy
+11,904
New +$230K ﹤0.01% 1689
2023
Q2 		– Sell
-1,554
Closed -$214K – 1758
2023
Q1 		$214K Buy
1,554
+4
+0.3% +$519 ﹤0.01% 1600
2022
Q4 		$201K Sell
1,550
-1,831
-54% -$212K ﹤0.01% 1606
2022
Q3 		$374K Sell
3,381
-985
-23% -$99.3K ﹤0.01% 1390
2022
Q2 		$327K Sell
4,366
-1,753
-29% -$129K ﹤0.01% 1512
2022
Q1 		$478K Sell
6,119
-1,119
-15% -$85.7K ﹤0.01% 1424
2021
Q4 		$652K Sell
7,238
-183
-2% -$15.6K ﹤0.01% 1369
2021
Q3 		$686K Buy
7,421
+1,640
+28% +$126K ﹤0.01% 1350
2021
Q2 		$449K Buy
5,781
+615
+12% +$46.6K ﹤0.01% 1434
2021
Q1 		$385K Buy
5,166
+806
+18% +$74.4K ﹤0.01% 1434
2020
Q4 		$743K Sell
4,360
-375
-8% -$55.6K ﹤0.01% 1118
2020
Q3 		$665K Buy
4,735
+253
+6% +$38.4K ﹤0.01% 1072
2020
Q2 		$719K Sell
4,482
-613
-12% -$83.4K ﹤0.01% 1042
2020
Q1 		$498K Buy
5,095
+546
+12% +$62.4K ﹤0.01% 1068
2019
Q4 		$587K Buy
4,549
+1,373
+43% +$139K ﹤0.01% 1125
2019
Q3 		$239K Buy
3,176
+1,576
+99% +$186K ﹤0.01% 1391
2019
Q2 		$244K Buy
+1,600
New +$194K ﹤0.01% 1400
2018
Q2 		– Sell
-3,005
Closed -$223K – 1318
2018
Q1 		$223K Sell
3,005
-5,683
-65% -$379K ﹤0.01% 1191
2017
Q4 		$483K Sell
8,688
-1,179
-12% -$62.5K ﹤0.01% 1025
2017
Q3 		$448K Buy
9,867
+998
+11% +$39.9K ﹤0.01% 1014
2017
Q2 		$299K Buy
8,869
+1,319
+17% +$42.9K ﹤0.01% 1090
2017
Q1 		$223K Buy
+7,550
New +$234K ﹤0.01% 1138

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Baird Financial Group's SRPT Position: Q2 2026 in Review

Baird Financial Group increased its Sarepta Therapeutics (SRPT) stake by 7.6% in Q2 2026, buying an estimated $17K and bringing the position to 12,805 shares worth $230K. The position accounts for ﹤0.01% of the portfolio, ranked #1827.

Baird Financial Group first reported a position in SRPT in Q1 2017 and has held it in 23 quarters since. The position peaked at $743K in Q4 2020. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Baird Financial Group held 12,805 shares of Sarepta Therapeutics worth $230K as of Q2 2026.
  • Baird Financial Group bought 901 Sarepta Therapeutics shares in Q2 2026, an estimated $17K.
  • Sarepta Therapeutics made up ﹤0.01% of Baird Financial Group's portfolio in Q2 2026, its #1827 holding.
  • Baird Financial Group first reported a position in Sarepta Therapeutics in Q1 2017 and has held it in 23 quarters since.
  • Baird Financial Group's Sarepta Therapeutics position peaked at $743K in Q4 2020.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Baird Financial Group's 13F filing for Q2 2026, filed 12 Aug 2026.